Arch Development Corporation

Kazuki Yasuda

Graeme I Bell

Terry Reisine

Philippe Froguel

Daniel Cohen

Habib Zouali

Nathalie Vionnet

Simon J Pilkis

Gilberto Velho

Markus Stoffel

Jun Takeda

The invention relates generally to compositions of and methods for obtaining opioid receptor polypeptides. The invention relates as well to polynucleotides encoding opioid receptor polypeptides, the recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, and recombinant opioid receptor polypeptides. By way of example, the invention discloses the cloning and functional expression of at least three different opioid receptor polypeptides. The invention includes as well, methods for using the isolated, recombinant receptor polypeptides in assays designed to select and improve substances capable of interacting with opioid receptor polypeptides for use in diagnostic, drug design and therapeutic applications.

Methods of identifying agonists and antagonists of opioid receptors

The invention relates generally to compositions of and methods for obtaining opioid receptor polypeptides. The invention relates as well to polynucleotides encoding opioid receptor polypeptides. More specifically, the invention relates to polynucleotides encoding kappa opioid receptor polypeptides, the recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, and recombinant opioid receptor polypeptides. By way of example, the invention discloses the cloning and functional expression of at least three different opioid receptor polypeptides. The invention includes as well, methods for using the isolated, recombinant receptor polypeptides in assays designed to select and improve substances capable of interacting with opioid receptor polypeptides for use in diagnostic, drug design and therapeutic applications.

Nucleic acids encoding kappa opioid receptors

The invention relates generally to compositions of and methods for using polynucleotides encoding kappa opioid receptors. In addition to such polynucleotides themselves, the invention relates to expression vectors comprising polynucleotides encoding kappa opioid receptors, recombinant host cells comprising such polynucleotides, and processes for preparing kappa opioid receptor polypeptides.

Polynucleotides encoding KAPPA opiod receptors

The invention relates to the observed tight linkage between DNA polymorphisms in the glucokinase gene (GCK) on the short arm of chromosome 7, and NIDDM in a cohort of sixteen French families having MODY. It further relates to identification of mutations in GCK and their linkage with diabetes in particular families are disclosed. This invention provides the first evidence implicating specific mutations in a gene involved in glucose metabolism in the pathogenesis of NIDDM. The invention further discloses the isolation and characterization of human pancreatic .beta.-cell GCK and a method for searching for mutations that cause early-onset NIDDM. To assess the effect of these mutations on glucokinase activity, a method is disclosed for generating an .alpha.-carbon backbone model for human glucokinase based on the crystal structure of the structurally-related yeast hexokinase B. Thus, in its most general sense, the invention relates to a method for detecting a propensity to develop early-onset, non-insulin-dependent diabetes mellitus.

Detection of glucokinase-linked early-onset non-insulin-dependent

Growing community of inventors

Machida, Japan

Kazuki Yasuda